Moleculin Biotech (MBRX) News Today $2.45 -0.15 (-5.77%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.comOctober 30 at 2:07 AM | americanbankingnews.comMoleculin Biotech Holds Successful 2024 Annual Meeting - Voting Results ReleasedOctober 29, 2024 | americanbankingnews.comMoleculin Biotech’s Annual Meeting Decisions and ElectionsOctober 26, 2024 | markets.businessinsider.comMoleculin Biotech Highlights Annamycin’s AML Treatment PotentialOctober 18, 2024 | finance.yahoo.comTranscript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now AvailableOctober 17, 2024 | prnewswire.comMoleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ...October 11, 2024 | uk.finance.yahoo.comMoleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024October 7, 2024 | prnewswire.comMoleculin to Present at Two Upcoming Investor ConferencesOctober 4, 2024 | prnewswire.comMoleculin Biotech IncSeptember 25, 2024 | money.usnews.comMoleculin Biotech Sees Positive Data From Annamycin StudySeptember 24, 2024 | marketwatch.comMoleculin Biotech Shares Rise 12% After Positive Annamycin DataSeptember 24, 2024 | marketwatch.comMoleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of SarcomaSeptember 23, 2024 | prnewswire.comMoleculin Participates in Virtual Investor "What this Means" SegmentSeptember 16, 2024 | prnewswire.comMoleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of GlioblastomaSeptember 9, 2024 | prnewswire.comMoleculin to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | prnewswire.comMoleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment WebinarAugust 26, 2024 | prnewswire.comMoleculin Announces Closing of up to $16.5 Million Public OfferingAugust 19, 2024 | prnewswire.comMoleculin sets terms for $5.5 million public offeringAugust 18, 2024 | uk.investing.comMoleculin Biotech gets Buy rating from Roth with strong trial resultsAugust 16, 2024 | investing.comMoleculin Announces Pricing of up to $16.5 Million Public OfferingAugust 16, 2024 | finance.yahoo.comMoleculin Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 14, 2024 | prnewswire.comMoleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ETAugust 5, 2024 | prnewswire.comBuy Rating for Moleculin Biotech on Promising Annamycin Trials and Undervalued SharesAugust 2, 2024 | markets.businessinsider.comMoleculin Announces Plans for MIRACLE Phase 3 Pivotal TrialAugust 1, 2024 | prnewswire.comMoleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AMLJuly 10, 2024 | prnewswire.comMoleculin Announces Additional Positive Preliminary Interim Data from AML Clinical TrialJune 14, 2024 | prnewswire.comMoleculin to Present at the Virtual Investor Pitch ConferenceJune 12, 2024 | prnewswire.comMoleculin to Participate in the Virtual Investor Lunch Break SeriesJune 5, 2024 | prnewswire.comMoleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid CongressMay 16, 2024 | prnewswire.comMoleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)May 15, 2024 | prnewswire.comMoleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2024 Earnings Call TranscriptMay 14, 2024 | msn.comMoleculin Biotech Inc (MBRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...May 14, 2024 | finance.yahoo.comMoleculin Biotech, Inc.: Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 13, 2024 | finanznachrichten.deMoleculin Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 13, 2024 | prnewswire.comMBRX Stock Earnings: Moleculin Biotech Beats EPS for Q1 2024May 10, 2024 | investorplace.comMoleculin Biotech’s Annamycin Shows Promising Efficacy in AML Treatment, Backed by Strong Clinical Results and Buy RatingMay 10, 2024 | markets.businessinsider.comMoleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for AnnamycinMay 9, 2024 | prnewswire.comMoleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and WebcastMay 8, 2024 | prnewswire.comMoleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject DataMay 7, 2024 | prnewswire.comMoleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024May 2, 2024 | prnewswire.comMoleculin Announces Formation of Scientific Advisory Board to Support Development of AnnamycinMay 1, 2024 | prnewswire.comJTC Team, LLC: Moleculin Biotech Participates in Virtual Investor "What This Means" Segment Hosted by JTC TeamApril 26, 2024 | finanznachrichten.deMoleculin Biotech Says EMA Grants Orphan Drug Designation To Annamycin To Treat AMLApril 18, 2024 | markets.businessinsider.comEuropean Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)April 18, 2024 | prnewswire.comMoleculin Biotech Inc (MBRX)April 12, 2024 | investing.comMoleculin Biotech Reveals Positive Anti-cancer Data For Annamycin With Non-cardiotoxic EffectsApril 10, 2024 | markets.businessinsider.comMoleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic PropertiesApril 10, 2024 | prnewswire.comMoleculin to Present at the MedInvest Biotech & Pharma Investor ConferenceMarch 28, 2024 | finance.yahoo.comMoleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AMLMarch 27, 2024 | finance.yahoo.comMoleculin to Participate in the Virtual Investor Lunch Break: The Moleculin OpportunityMarch 27, 2024 | prnewswire.com Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here MBRX Media Mentions By Week MBRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MBRX News Sentiment▼0.410.43▲Average Medical News Sentiment MBRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MBRX Articles This Week▼21▲MBRX Articles Average Week Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VCNX News Today PLUR News Today ITRM News Today LSTA News Today UBX News Today APRE News Today TNXP News Today CGTX News Today PIRS News Today CYTH News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MBRX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
